NIH Licensing Opportunity: A Class of Small Molecule Phenylalanine Derivatives as Potential Payloads for Cancer-Targeted Delivery Systems

NIH Licensing Opportunity: A Class of Small Molecule Phenylalanine Derivatives as Potential Payloads for Cancer-Targeted Delivery Systems

 

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

Inhibition of Cancer Cell Migration, Invasion and Angiogenesis

This ground-breaking class of small molecule phenylalanine derivatives inhibit Growth Factor Receptor-Bound Protein 2 activity and inhibit cancer cell migration, invasion and angiogenesis.

The adaptor protein growth factor receptor-bound-2 (Grb2) is a critical signaling mediator of several growth factor receptors and intracellular tyrosine kinases that drive cell motililty, proliferation and morphogenesis.

Signaling is initiated through a selective, high affinity binding interaction between the Grb2 Src homology type-2 (SH2) domain and specific phosphotyrosyl-containing motifs in activated tyrosine kinases and enables the formation of multimolecular signaling complexes that link kinases to key downstream regulatory networks.

Exploiting unique structural features of this interaction, small synthetic peptidomimetic Grb2 SH2 domain antagonists were rationally designed and developed that bind tightly and selectively to the Grb2 SH2 domain, thereby blocking its interaction with activated tyrosine kinases. These competitive binding antagonists potently inhibit growth factor stimulated cell motility, matrix invasion and branching morphogenesis in model cultured cell systems, with IC₅₀ values of 30 nM or less, block angiogenesis in the avian CAM assay, and block tumor metastasis in animal models.

These Grb2 SH2 domain antagonists may have the potential to act as a payload for cancer-targeted therapeutic delivery systems.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

 

---

PANELISTS
	SPEAKER: Terrence Burke Jr., PhD Head, Bioorganic Chemistry Section National Cancer Institute Center for Cancer Research (CCR)
	SPEAKER: Donald P. Bottaro, PhD Head, Molecular Therapeutics Facility National Cancer Institute Center for Cancer Research (CCR)
	MODERATOR: Dawn Van Dam Executive Director & CEO One Million Solutions in Health™

REGISTER ME FOR THIS SIGNATURE SQUARE EVENT: Click HERE